NO791557L - Fremgangsmaate for fremstilling av et preparat for aa redusere fenylalanininnholdet i blodet - Google Patents
Fremgangsmaate for fremstilling av et preparat for aa redusere fenylalanininnholdet i blodetInfo
- Publication number
- NO791557L NO791557L NO791557A NO791557A NO791557L NO 791557 L NO791557 L NO 791557L NO 791557 A NO791557 A NO 791557A NO 791557 A NO791557 A NO 791557A NO 791557 L NO791557 L NO 791557L
- Authority
- NO
- Norway
- Prior art keywords
- phenylalanine
- blood
- preparation
- enzyme
- preparing
- Prior art date
Links
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 title claims description 31
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 title claims description 31
- 239000008280 blood Substances 0.000 title claims description 17
- 210000004369 blood Anatomy 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000000835 fiber Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 claims description 3
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- BTNMPGBKDVTSJY-UHFFFAOYSA-N keto-phenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-N 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 201000011252 Phenylketonuria Diseases 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000001903 2-oxo-3-phenylpropanoic acid Substances 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- DEDGUGJNLNLJSR-UHFFFAOYSA-N alpha-hydroxycinnamic acid Natural products OC(=O)C(O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920002284 Cellulose triacetate Polymers 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- UUCMDZWCRNZCOY-UHFFFAOYSA-N ditazole Chemical compound O1C(N(CCO)CCO)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UUCMDZWCRNZCOY-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 description 1
- RSTKLPZEZYGQPY-UHFFFAOYSA-N 3-(indol-3-yl)pyruvic acid Chemical compound C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1 RSTKLPZEZYGQPY-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000223253 Rhodotorula glutinis Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT23336/78A IT1096208B (it) | 1978-05-12 | 1978-05-12 | Composizione adatta alla riduzione del tenore di fenilalanina e metodo impiegante la stessa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO791557L true NO791557L (no) | 1979-11-13 |
Family
ID=11206197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO791557A NO791557L (no) | 1978-05-12 | 1979-05-09 | Fremgangsmaate for fremstilling av et preparat for aa redusere fenylalanininnholdet i blodet |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4248704A (fr) |
| JP (1) | JPS54147909A (fr) |
| AU (1) | AU521742B2 (fr) |
| BE (1) | BE876204A (fr) |
| CA (1) | CA1130206A (fr) |
| CS (1) | CS214795B2 (fr) |
| DD (1) | DD143730A5 (fr) |
| DE (1) | DE2919127C2 (fr) |
| DK (1) | DK182479A (fr) |
| FR (1) | FR2425246A1 (fr) |
| GB (1) | GB2020668B (fr) |
| HU (1) | HU181954B (fr) |
| IL (1) | IL57251A (fr) |
| IT (1) | IT1096208B (fr) |
| LU (1) | LU81242A1 (fr) |
| NL (1) | NL7903789A (fr) |
| NO (1) | NO791557L (fr) |
| SE (1) | SE7904161L (fr) |
| ZA (1) | ZA792249B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU194487B (en) * | 1979-12-28 | 1988-02-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing food-preparation suitable for feeding sicks of phenylketoneurea from protein hydrolysates |
| DE3167008D1 (en) | 1980-02-13 | 1984-12-13 | Sorin Biomedica Spa | Method of immobilizing an enzyme in a bundle of cellulosic fibres for a fibre-bundle dialyzer for purifying blood |
| JPS56145857A (en) * | 1980-04-15 | 1981-11-12 | Unitika Ltd | Material for purifying body fluid and its manufacture |
| US4562151A (en) * | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
| JPS61353A (ja) * | 1984-06-13 | 1986-01-06 | テルモ株式会社 | 薬剤投与装置 |
| JPH0655223B2 (ja) * | 1986-05-06 | 1994-07-27 | 宇部興産株式会社 | 非生物学的吸着剤 |
| US4955857A (en) * | 1988-07-18 | 1990-09-11 | Shettigar Udipi R | Multi-enzyme bioreactor therapy for cancer |
| US5324253A (en) * | 1992-03-02 | 1994-06-28 | Mcrea James C | Cannula apparatus and system for heparin removal from blood |
| DK75593D0 (fr) * | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| WO1995004560A1 (fr) * | 1993-08-10 | 1995-02-16 | Ao-Forschungsinstitut Davos | Traitement de tumeurs par epuisement proteique selectif |
| US5868936A (en) * | 1996-06-20 | 1999-02-09 | Baxter International Inc. | Affinity membrane system and method of using same |
| CN116114787A (zh) * | 2023-03-16 | 2023-05-16 | 中国农业科学院农产品加工研究所 | 一种高效脱除蛋白原料中苯丙氨酸的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL269380A (fr) * | 1960-09-19 | |||
| US3441142A (en) * | 1966-07-21 | 1969-04-29 | Dow Chemical Co | Nonthrombogenic plastic membranes |
| US3522346A (en) * | 1968-05-31 | 1970-07-28 | Research Corp | Nonthrombogenic microcapsules |
| IL32406A (en) * | 1968-06-26 | 1973-01-30 | Snam Progetti | Enzyme preparations comprising a solution or dispersion of enzyme occluded in filaments of cellulose esters or synthetic polymers |
| US3673612A (en) * | 1970-08-28 | 1972-07-04 | Massachusetts Inst Technology | Non-thrombogenic materials and methods for their preparation |
| US3809613A (en) * | 1971-05-28 | 1974-05-07 | Research Corp | Biocatalytic module |
| JPS5136810B2 (fr) * | 1972-08-04 | 1976-10-12 | ||
| US4004980A (en) * | 1975-03-25 | 1977-01-25 | Purdue Research Foundation | Enzyme entrappment with cellulose acetate formulations |
| US4051040A (en) * | 1976-03-17 | 1977-09-27 | John L. Hutchinson | Antithrombogenic hemo dialysis membranes |
| JPS5340691A (en) * | 1976-04-01 | 1978-04-13 | Korufu Fuaundeeshiyon Za | Method and apparatus for removing impurities from fluids |
| IT1085524B (it) * | 1977-03-22 | 1985-05-28 | Snam Progetti | Materiali e fibre porose biocompatibili in grado di inglobare sostanze di interesse biologico e metodi per il loro ottenimento |
-
1978
- 1978-05-12 IT IT23336/78A patent/IT1096208B/it active
-
1979
- 1979-05-03 DK DK182579A patent/DK182479A/da unknown
- 1979-05-03 US US06/035,528 patent/US4248704A/en not_active Expired - Lifetime
- 1979-05-09 ZA ZA792249A patent/ZA792249B/xx unknown
- 1979-05-09 GB GB7916059A patent/GB2020668B/en not_active Expired
- 1979-05-09 AU AU46895/79A patent/AU521742B2/en not_active Ceased
- 1979-05-09 NO NO791557A patent/NO791557L/no unknown
- 1979-05-10 DD DD79212783A patent/DD143730A5/de unknown
- 1979-05-10 FR FR7911923A patent/FR2425246A1/fr active Granted
- 1979-05-10 LU LU81242A patent/LU81242A1/fr unknown
- 1979-05-11 HU HU79SA3181A patent/HU181954B/hu unknown
- 1979-05-11 SE SE7904161A patent/SE7904161L/ not_active Application Discontinuation
- 1979-05-11 CA CA327,577A patent/CA1130206A/fr not_active Expired
- 1979-05-11 IL IL57251A patent/IL57251A/xx unknown
- 1979-05-11 JP JP5718979A patent/JPS54147909A/ja active Pending
- 1979-05-11 BE BE0/195119A patent/BE876204A/fr not_active IP Right Cessation
- 1979-05-11 DE DE2919127A patent/DE2919127C2/de not_active Expired
- 1979-05-12 CS CS793256A patent/CS214795B2/cs unknown
- 1979-05-14 NL NL7903789A patent/NL7903789A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU521742B2 (en) | 1982-04-29 |
| JPS54147909A (en) | 1979-11-19 |
| IL57251A (en) | 1982-04-30 |
| BE876204A (fr) | 1979-11-12 |
| CS214795B2 (en) | 1982-05-28 |
| CA1130206A (fr) | 1982-08-24 |
| IL57251A0 (en) | 1979-09-30 |
| US4248704A (en) | 1981-02-03 |
| FR2425246B1 (fr) | 1983-08-05 |
| IT1096208B (it) | 1985-08-26 |
| NL7903789A (nl) | 1979-11-14 |
| DE2919127A1 (de) | 1979-11-22 |
| HU181954B (en) | 1983-11-28 |
| DD143730A5 (de) | 1980-09-10 |
| IT7823336A0 (it) | 1978-05-12 |
| DK182479A (da) | 1979-11-13 |
| GB2020668A (en) | 1979-11-21 |
| AU4689579A (en) | 1979-11-15 |
| DE2919127C2 (de) | 1982-10-21 |
| SE7904161L (sv) | 1979-11-13 |
| FR2425246A1 (fr) | 1979-12-07 |
| LU81242A1 (fr) | 1979-09-10 |
| GB2020668B (en) | 1982-09-08 |
| ZA792249B (en) | 1980-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eriksson et al. | Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis | |
| AU701724B2 (en) | Biochemically balanced peritoneal dialysis solutions | |
| NO791557L (no) | Fremgangsmaate for fremstilling av et preparat for aa redusere fenylalanininnholdet i blodet | |
| Lortie et al. | Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional effects in the kidney of the rat. | |
| Brückner et al. | Gas chromatographic characterization of free D-amino acids in the blood serum of patients with renal disorders and of healthy volunteers | |
| FR2501692A1 (fr) | Nouveau produit d'erythropoietine et procede pour sa preparation | |
| JPH08508300A (ja) | マルトデキストリン及びアミノ酸を含有する腹膜透析液 | |
| Nagase et al. | Biosynthesis of methylguanidine in isolated rat hepatocytes and in vivo | |
| FR2497229A1 (fr) | Procede de preparation d'un derive polysaccharidique de fibrinolysine | |
| JPH11502875A (ja) | 臨床用のマイクロカプセル封入遺伝子操作微生物 | |
| NZ211101A (en) | Glucose polymer containing compositions for use in peritoneal dialysis | |
| Magnusson et al. | N-acetyl-L-tyrosine and N-acetyl-L-cysteine as tyrosine and cysteine precursors during intravenous infusion in humans | |
| Owen et al. | The effect of induced hyperammonemia on renal ammonia metabolism | |
| JPS6042207B2 (ja) | 胎盤よりプラスミノ−ゲン型活性化合物を抽出する方法 | |
| Puliyanda et al. | Utility of hemodialysis in maple syrup urine disease | |
| CN100355452C (zh) | 羰基应激改良剂 | |
| Weinberg et al. | Racemization and amination of the keto-analog of isoleucine in the intact dog | |
| CN100593420C (zh) | 一种内皮抑素结合物及其制备方法 | |
| Bories et al. | Lecithin: cholesterol acyltransferase activity in dialyzed and undialyzed chronic uremic patients | |
| Tsukada et al. | Effect of 6R-L-erythro-5, 6, 7, 8-tetrahydrobiopterin on the extracellular levels of dopamine and serotonin in the rat striatum: a microdialysis study with tyrosine or tryptophan infusion | |
| Pagliassotti et al. | Increased net hepatic glucose output from gluconeogenic precursors after high-sucrose diet feeding in male rats | |
| Borland et al. | Serum oxalate in chronic renal failure | |
| Ratge et al. | Distribution of free and conjugated catecholamines between plasma, platelets and erythrocytes: different effects of intravenous and oral catecholamine administrations. | |
| JPS6236040B2 (fr) | ||
| AU598721B2 (en) | Method of lowering blood sugar level in vertebrates |